NASDAQ$OBIO
Orchestra Biomed Holdings In · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Orchestra BioMed reported Q2 2025, revenue of $836M, net loss of $19.36B.
For Q2 2025, Orchestra BioMed reported revenue of $836M, a net loss of $19.36B. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $836M.
- Net loss $19.36B.
- Orchestra BioMed highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Orchestra Biomed · Revenue · Quarterly
$836K
Revenue by segment
Orchestra Biomed · $2.64M total across 2 segments · Q4 2024
- Partnership revenue$2.01M-4.8%76.0%
- Product revenue$633K-3.2%24.0%
Forward guidance
The release discusses Orchestra BioMed's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Orchestra BioMed cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q2 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2025
+4.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+5.7%
Avg return
30 days after
63%
12 / 19 earnings
Positive
+30.5%
Q4 2022
Best reaction
-6.0%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -4.9% | +4.1% | |
| Q4 2025 | +4.7% | +4.9% | -2.0% | |
| Q3 2025 | +4.6% | +12.4% | +9.1% | |
| Q2 2025 | -2.6% | +1.8% | +4.0% | |
| Q1 2025 | +0.3% | -5.9% | +16.6% | |
| Q4 2024 | -6.0% | -4.4% | -11.1% | |
| Q3 2024 | -1.0% | -4.7% | -12.9% | |
| Q2 2024 | -3.7% | +3.7% | -8.1% | |
| Q1 2024 | +10.4% | +10.6% | +68.6% | |
| Q4 2023 | +0.2% | -5.9% | -16.5% | |
| Q3 2023 | +29.6% | +28.8% | +58.3% | |
| Q2 2023 | +5.3% | -0.5% | +9.2% | |
| Q1 2023 | +2.5% | +15.3% | -16.8% | |
| Q4 2022 | +30.5% | -12.1% | -1.6% | |
| Q3 2022 | +0.3% | -0.4% | +0.1% | |
| Q2 2022 | +0.0% | +0.1% | +0.2% | |
| Q4 2021 | +0.0% | +0.2% | +0.4% | |
| Q1 2022 | +0.0% | +0.2% | +0.4% | |
| Q1 2021 | +3.7% | +1.8% | +6.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro